

TheraVet announces the appointment of a Chief Financial Officer to reinforce its global financing and cost control strategy

Gosselies (Wallonia, Belgium), October 25, 2023 - 7.30 am CEST - TheraVet (ISIN: BE0974387194 - ticker: ALVET), a pioneering company in the management of osteoarticular diseases in pets, today announced **the appointment of Rodolphe Lebrun as Chief Financial Officer.**

Enrico Bastianelli, Chief Executive Officer of TheraVet, stated: *"We are delighted to welcome Rodolphe as Chief Financial Officer. His profile, marked by strong financial and engineering skills, is fully in line with the DNA of our Company. Rodolphe already boasts solid experience, whether as a consultant, sales manager or CFO, enabling him to fully grasp the challenges of the biotech world. **His expertise will be a key asset in pursuing and strengthening our global financing and cost control strategy.**"*

Since 2016, **Rodolphe acts as a strategic advisor to small and large biotech and medtech companies on their financing, business development and M&A activities.** Before joining TheraVet, Rodolphe Lebrun held the position of CFO at Graftys, an orthobiology company specialized in the development, manufacture and marketing of calcium phosphate-based synthetic bone substitutes, during the year 2020, marked by the onset of the Covid-19 pandemic. In this position, he was involved through active cost management and the implementation of non-dilutive financing, enabling the company to successfully navigate in this uncertain period. Prior to this, he was for over 2 years Director of KPMG Belgium's Life Sciences Practice, paying particular attention to R&D-related topics as well as marketing and operational strategy. Between 2014 and 2016, he worked for the biotech company AbbVie as Customer Excellence Director and member of its Executive Committee for Belgium and Luxembourg. Prior to this, Rodolphe spent almost 5 years with McKinsey & Company, where he was focused on defining operational strategy and leading operational excellence transformations in major pharmaceutical and medtech groups, as well as hospitals.

Rodolphe is a graduate of the Faculté Polytechnique de Mons, the Institut Supérieur de l'Aéronautique et de l'Espace (ISAE Toulouse) and the Solvay Brussels School of Economics and Management.

Rodolphe's role in TheraVet will be **to optimize the Company's financial structure to ensure rigorous allocation of financial resources, and to implement and execute the Company's financial strategy. He will also be responsible for pursuing and strengthening the**



Company's cost control policy, and for managing the Company's cash flow on a day-to-day basis.

About TheraVet SA

TheraVet is a veterinary biotechnology company specializing in osteoarticular treatments for companion animals. The Company develops targeted, safe and effective treatments to improve the quality of life of pets suffering from joint and bone diseases. For pet owners, the health of their pets is a major concern and TheraVet's mission is to address the need for innovative and curative treatments. TheraVet works closely with international opinion leaders in order to provide a more effective response to ever-growing needs in the field of veterinary medicine. TheraVet is listed on Euronext Growth® Paris and Brussels, has its head office in Belgium (Gosselies) with a US subsidiary.

For more information, visit the TheraVet [website](#) or follow us on [LinkedIn](#) / [Facebook](#) / [Twitter](#)

Contacts

TheraVet

Chief Operating Officer
Sabrina Ena
investors@thera.vet
Tel: +32 (0) 71 96 00 43

NewCap

Investor Relations and
Financial Communications
Théo Martin / Nicolas Fossiez
theravet@newcap.eu
Tel: +33 (0)1 44 71 94 94

NewCap Belgique

Press Relations
Laure-Eve Monfort
lemonfort@thera.vet
Tel: + 32 (0) 489 57 76 52

Press Relations
Arthur Rouillé
theravet@newcap.eu
Tel: +33 (0)1 44 71 00 15